Log in
ACP

ACP 2023 living guideline: acute-phase treatment of major depressive disorder

This ACP living clinical guideline addresses how to treat adults with major depressive disorder during the acute phase, comparing nonpharmacologic and pharmacologic options including second-generation antidepressants and psychotherapy. The main message is that second-generation antidepressants and psychotherapy (especially cognitive behavioral therapy) have similar effectiveness for acute treatment, and the choice should be guided by patient preference, cost, access, and prior treatment response.

ACP2023 editionSummary
Official guidelineNonpharmacologic and Pharmacologic Treatments of Adults in the Acute Phase of Major Depressive Disorder: A Living Clinical Guideline From the American College of Physicians. ACP, 2023.
Read the official guideline · Checked for a newer edition on 2026-10-20
We do not reproduce the guideline text — this page is an independent summary.

Who it applies to

Adults with major depressive disorder being treated in outpatient settings during the acute phase of illness.

Key recommendations

  • Clinicians should select between second-generation antidepressants and cognitive behavioral therapy based on patient preference, as both show similar efficacy for acute treatment of moderate to severe major depressive disorder.
  • Discussion of adverse effect profiles, cost, availability, and patient prior experience should guide selection of a specific second-generation antidepressant when drug therapy is chosen.
  • Second-generation antidepressants include SSRIs, SNRIs, bupropion, mirtazapine, and related newer agents, and no single second-generation antidepressant is clearly superior in efficacy to the others.
  • Psychotherapy options with evidence of benefit include cognitive behavioral therapy and other structured psychotherapies, which can be used alone or in combination with medication.
  • Combination therapy with both an antidepressant and psychotherapy may be considered, particularly when single-modality treatment is insufficient or in more severe presentations.
  • For patients who do not respond to initial treatment, options include switching to a different antidepressant, augmenting with another agent, or switching to or adding psychotherapy.
  • The guideline emphasizes shared decision-making, incorporating patient values and preferences given the broadly similar effectiveness across first-line treatment options.
  • As a living guideline, recommendations are intended to be updated as new evidence emerges rather than representing a fixed, time-limited document.

Practice points for students

  • No single second-generation antidepressant has proven superiority over others for acute major depressive disorder, so tolerability and patient preference drive selection.
  • Cognitive behavioral therapy is a reasonable first-line alternative to medication, not just an adjunct.
  • This is a living guideline, meaning it may be revised on a rolling basis rather than at fixed multi-year intervals.
  • Shared decision-making is central given the evidence of comparable efficacy among major treatment options.

Condition

Major depressive disorder

Other guidelines on this topic

Independent educational summary written by the WhiteCoat Pro editorial team with AI assistance and checked by a second AI model. It does not reproduce the guideline text, tables or figures, and it is not affiliated with or endorsed by ACP. It is not medical advice: always read the original guideline before applying it to patients.